FindTrial
Sign In

Effects of autologous serum on toxic corneal epitheliopathy

Effects of topical autologous serum on the ocular surface in patients with toxic corneal epitheliopathy induced by anti-glaucoma drugs

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0003827
Enrollment
10
Registered
2019-04-19
Start date
2018-04-11
Completion date
Unknown
Last updated
2019-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Seoul National University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients were included when the fluorescein corneoconjunctival staining score was 5 or more as determined by NEI/Industry Grading System after treatment with non-preserved artificial tears for longer than one month.

Exclusion criteria

Exclusion criteria: Patients were excluded when they were under the age of 18 years or if there was a history of ocular surface disorders such as Sjögren’s syndrome, ocular trauma or surgery aside from cataract surgery.

Design outcomes

Primary

MeasureTime frame
subjective dry eye symptoms as assessed by the Ocular Surface Disease Index (OSDI) questionnaire;the tear film break-up time (TFBUT);Aqueous tear secretion as evaluated by Schirmer I test;Coneoconjunctival staining scores graded by NEI/Industry Grading System—

Secondary

MeasureTime frame
Cntral corneal sensitivity;InflammaDry® tear immunoassay (RPS Diagnostics, Sarasota, FL, USA) for metalloproteinase-9 level;tear cytokine profiles—

Countries

Korea, Republic of

Contacts

Public ContactChang Ho Yoon

Seoul National University Hospital

ifree7@gmail.com+82-2-2072-1488

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Mar 1, 2026